Serious flaws in study which says Covishield produces more antibodies, reacts Bharat Biotech

June 9: In a recent study, it was claimed that Covishield produces more anti-bodies against coronavirus than Covaxin. However, taking a dig at this claim, Covaxin maker Bharat Biotech pointed out that there are several flaws in the study. It said that the study has not been peer-reviewed and moreover, the research was not scientifically designed and was conducted on an adhoc basis, rather than a predetermined hypothesis. Further, the study was not registered on CTRI website, nor approved by CDSCO and SEC.

Bharat Biotech also stated that the Phase 3 data of Covaxin’s trial will be published in July and the firm will then apply for full licensure of the Indian vaccine.